Cagrilintide: Evidence, Uses and Risks
Also known as: AM833
An investigational once-weekly amylin analog studied for weight management on its own and, more prominently, in combination with semaglutide. It is not yet FDA-approved.
Key takeaways
- Cagrilintide is an investigational once-weekly amylin analog; it is not FDA-approved alone or in the CagriSema combination.
- In a 706-person phase 2 trial, 26 weeks of cagrilintide produced 6.0–10.8% weight loss (0.3–4.5 mg) versus 3.0% with placebo. [1]
- The 4.5 mg dose beat liraglutide 3.0 mg (10.8% vs 9.0%), with similar discontinuation rates across groups. [1]
- Amylin slows gastric emptying and promotes fullness through its own receptors, complementing GLP-1 action.
- Phase 3 CagriSema results will decide whether dual amylin/GLP-1 action beats semaglutide alone; until then it is trial-only.
What is Cagrilintide?
Cagrilintide (development code AM833) is an investigational once-weekly injectable peptide from Novo Nordisk. It is a long-acting analog of amylin, a hormone co-secreted with insulin by the pancreas that helps regulate appetite and fullness. It has drawn the most attention as the amylin half of CagriSema, an investigational combination with semaglutide.
As of 2026, cagrilintide is not FDA-approved, either on its own or as part of CagriSema. It is a clinical-trial compound, not something a legitimate clinic can compound or dispense, and Strong Health does not provide it.
What does the evidence show for Cagrilintide?
In a phase 2 dose-finding trial of 706 people with overweight or obesity, published in The Lancet in 2021, once-weekly cagrilintide produced 6.0–10.8% weight loss over 26 weeks versus 3.0% with placebo [1]. The 4.5 mg dose outperformed liraglutide 3.0 mg (10.8% vs 9.0%), and the drug was generally well tolerated.
Cagrilintide's larger story is combination therapy: trials of CagriSema (cagrilintide plus semaglutide) have been the main driver of interest, testing whether dual amylin/GLP-1 action outperforms GLP-1 alone.
As with any investigational agent, phase 2 data establish a signal, not a settled treatment. Long-term safety, durability, and the full CagriSema outcome picture depend on phase 3 results, and we present this honestly rather than as an available therapy.
| Trial | Participants | Design | Result |
|---|---|---|---|
| Phase 2 dose-finding (Lau 2021) | 706 adults with overweight or obesity | 26 weeks; cagrilintide 0.3–4.5 mg vs liraglutide 3.0 mg vs placebo | Weight −6.0% to −10.8% vs −3.0% placebo; 4.5 mg beat liraglutide (−10.8% vs −9.0%) |
| Phase 1b CagriSema | 96 adults | Cagrilintide co-escalated with semaglutide 2.4 mg over 16 weeks | Combination tolerated; informed phase 3 program |
| Phase 3 (REDEFINE program) | Ongoing | CagriSema vs components and placebo | Results pending; not approved |
Treatment with cagrilintide in people with overweight and obesity led to significant reductions in bodyweight and was well tolerated.
What are the risks and unknowns for Cagrilintide?
Cagrilintide is investigational and not FDA-approved. This page is educational, physician-reviewed context, not medical advice, a dosing guide, or an offer to prescribe. Strong Health does not provide cagrilintide.
The most common side effects reported in trials are gastrointestinal: nausea, reduced appetite, and related symptoms, consistent with appetite-regulating therapies and generally dose-related. Injection-site reactions have also been reported.
Long-term safety is not established, since cagrilintide remains in development. Its complete risk profile and outcomes over years of use are not yet known, which is a central reason we do not offer it.
Side effects and safety considerations
- ·Nausea
- ·Reduced appetite
- ·Constipation or diarrhea
- ·Injection-site reactions
- ·Vomiting (less common)
Who should not use it
- ·Pregnancy or breastfeeding
- ·Known hypersensitivity to the compound
- ·Personal or family history of medullary thyroid carcinoma or MEN 2 (relevant when combined with a GLP-1)
- ·Use outside a clinical trial (cagrilintide is investigational and not FDA-approved)
How does Cagrilintide work?
Amylin works alongside GLP-1 through a different pathway: it promotes satiety, slows gastric emptying, and helps regulate how quickly you feel full and how much you eat. Cagrilintide is engineered to mimic amylin with a long enough duration of action for once-weekly dosing.
The strategic interest in cagrilintide is combination therapy. Pairing an amylin analog (cagrilintide) with a GLP-1 agonist (semaglutide) engages two complementary appetite-regulating systems at once, which is the premise behind CagriSema and the reason cagrilintide is usually discussed in that context.
Which uses are discussed for Cagrilintide?
Obesity and weight management
The central focus of cagrilintide's development: reducing body weight in adults with overweight or obesity, dose-dependently in early trials.
Combination with semaglutide (CagriSema)
Studied together with semaglutide to engage both amylin and GLP-1 appetite pathways, the combination that has generated the most clinical interest.
Type 2 diabetes (investigational)
Explored with semaglutide for glycemic control alongside weight reduction in people with type 2 diabetes.
What should you know about Cagrilintide dosing?
In trials, cagrilintide is administered as a once-weekly subcutaneous injection with gradual dose escalation, and in the combination program it is co-administered with semaglutide. Trial dosing follows study protocols, not patient self-titration.
Because cagrilintide is investigational, there is no approved label, no approved dose, and no legitimate compounded or retail supply. Product sold online as 'cagrilintide' outside a trial is unverified for identity, purity, and sterility. That is the gray-market risk our clinical model exists to avoid.
Why Strong Health does not offer Cagrilintide
Strong Health does not prescribe or provide cagrilintide or CagriSema. Both are investigational, not FDA-approved, and available only through clinical trials, not as compounded or research-grade products. Providing an unapproved novel molecule outside a trial would be inconsistent with the law and with our standards.
We document cagrilintide because patients ask about it and deserve a clear, physician-reviewed picture of where the evidence stands. For medically supervised weight loss now, our physicians evaluate FDA-cleared and appropriately compounded options and build a monitored protocol around your labs rather than chasing the newest unapproved compound.
Interested in medically supervised weight loss? Talk to one of our physicians about FDA-approved and appropriately compounded options with real clinical monitoring, or explore our physician-reviewed guides.
Talk to a physician about weight loss →See our guide to peptides for weight loss, peptides for belly & visceral fat, or the full molecule library.
Frequently asked questions
Is cagrilintide FDA-approved?
What is CagriSema?
How is cagrilintide different from semaglutide?
Can I get cagrilintide at Strong Health?
References & sources
- [90] FDA. Human Drug Compounding. Accessed November 3, 2026. View source →
- [91] HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. October 2026; accessed November 3, 2026. View source →
- [1] Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. View source →